TENOFOVIR: 4,066 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
4,066
Total FAERS Reports
600 (14.8%)
Deaths Reported
803
Hospitalizations
4,066
As Primary/Secondary Suspect
110
Life-Threatening
43
Disabilities
First Report: 19960101 · Latest Report: 20250821
What Are the Most Common TENOFOVIR Side Effects?
#1 Most Reported
Foetal exposure during pregnancy
509 reports (12.5%)
#2 Most Reported
Virologic failure
409 reports (10.1%)
#3 Most Reported
Drug resistance
317 reports (7.8%)
All TENOFOVIR Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Foetal exposure during pregnancy | 509 | 12.5% | 95 | 41 |
| Virologic failure | 409 | 10.1% | 10 | 10 |
| Drug resistance | 317 | 7.8% | 9 | 26 |
| Exposure during pregnancy | 292 | 7.2% | 10 | 21 |
| Death | 225 | 5.5% | 224 | 17 |
| Immune reconstitution inflammatory syndrome | 177 | 4.4% | 33 | 75 |
| Maternal exposure during pregnancy | 173 | 4.3% | 17 | 28 |
| Treatment failure | 163 | 4.0% | 2 | 7 |
| Drug interaction | 141 | 3.5% | 13 | 48 |
| Premature baby | 126 | 3.1% | 22 | 6 |
| Drug ineffective | 125 | 3.1% | 46 | 23 |
| Acute kidney injury | 122 | 3.0% | 33 | 68 |
| Premature delivery | 110 | 2.7% | 0 | 8 |
| Treatment noncompliance | 105 | 2.6% | 4 | 21 |
| Renal impairment | 90 | 2.2% | 6 | 23 |
| Pathogen resistance | 86 | 2.1% | 0 | 15 |
| Condition aggravated | 80 | 2.0% | 51 | 29 |
| Fanconi syndrome | 80 | 2.0% | 8 | 46 |
| Lipodystrophy acquired | 75 | 1.8% | 0 | 4 |
| Csf hiv escape syndrome | 73 | 1.8% | 5 | 14 |
Who Reports TENOFOVIR Side Effects? Age & Gender Data
Gender: 43.2% female, 56.8% male. Average age: 43.9 years. Most reports from: US. View detailed demographics →
Is TENOFOVIR Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 2 | 0 | 0 |
| 2002 | 4 | 0 | 0 |
| 2003 | 5 | 1 | 1 |
| 2004 | 6 | 0 | 5 |
| 2005 | 14 | 0 | 1 |
| 2006 | 12 | 0 | 3 |
| 2007 | 4 | 0 | 3 |
| 2008 | 7 | 0 | 4 |
| 2009 | 11 | 1 | 2 |
| 2010 | 36 | 7 | 27 |
| 2011 | 22 | 1 | 5 |
| 2012 | 34 | 8 | 17 |
| 2013 | 31 | 5 | 15 |
| 2014 | 73 | 17 | 41 |
| 2015 | 56 | 6 | 33 |
| 2016 | 33 | 2 | 11 |
| 2017 | 50 | 14 | 22 |
| 2018 | 124 | 21 | 38 |
| 2019 | 64 | 1 | 13 |
| 2020 | 45 | 14 | 12 |
| 2021 | 51 | 6 | 10 |
| 2022 | 28 | 2 | 6 |
| 2023 | 38 | 11 | 3 |
| 2024 | 32 | 1 | 10 |
| 2025 | 13 | 1 | 6 |
What Is TENOFOVIR Used For?
| Indication | Reports |
|---|---|
| Hiv infection | 2,192 |
| Product used for unknown indication | 466 |
| Antiretroviral therapy | 243 |
| Hepatitis b | 200 |
| Chronic hepatitis b | 187 |
| Prophylaxis against hiv infection | 155 |
| Acquired immunodeficiency syndrome | 37 |
| Prophylaxis | 31 |
| Antiviral prophylaxis | 28 |
| Hiv infection who clinical stage iii | 25 |
TENOFOVIR vs Alternatives: Which Is Safer?
TENOFOVIR vs TENOFOVIR ALAFENAMIDE
TENOFOVIR vs TENOFOVIR DISOPROXIL
TENOFOVIR vs TEPLIZUMAB-MZWV
TENOFOVIR vs TEPOTINIB
TENOFOVIR vs TEPROTUMUMAB
TENOFOVIR vs TEPROTUMUMAB-TRBW
TENOFOVIR vs TERAZOSIN
TENOFOVIR vs TERAZOSIN\TERAZOSIN
TENOFOVIR vs TERBINAFINE
TENOFOVIR vs TERBINAFINE\TERBINAFINE
Official FDA Label for TENOFOVIR
Official prescribing information from the FDA-approved drug label.